You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
|
|---|---|
| Published in |
Lancet Oncology, March 2008
|
| DOI | 10.1016/s1470-2045(08)70069-x |
| Pubmed ID | |
| Authors |
Andrew DJ Pearson, C Ross Pinkerton, Ian J Lewis, John Imeson, Caroline Ellershaw, David Machin, for the European Neuroblastoma Study Group, the Children's Cancer and Leukaemia Group |
| Abstract |
The current standard treatment for patients with high-risk neuroblastoma includes initial induction chemotherapy with a 21-day interval between induction treatments. We aimed to assess whether an intensive chemotherapy protocol that had a 10-day interval between treatments would improve event-free survival (EFS) in patients aged 1 year or over with high-risk neuroblastoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| Italy | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 163 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 25 | 15% |
| Student > Master | 20 | 12% |
| Student > Bachelor | 17 | 10% |
| Researcher | 14 | 8% |
| Student > Postgraduate | 8 | 5% |
| Other | 39 | 23% |
| Unknown | 44 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 34% |
| Biochemistry, Genetics and Molecular Biology | 21 | 13% |
| Agricultural and Biological Sciences | 11 | 7% |
| Unspecified | 7 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 16 | 10% |
| Unknown | 52 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2024.
All research outputs
#2,258,032
of 26,017,215 outputs
Outputs from Lancet Oncology
#2,245
of 6,958 outputs
Outputs of similar age
#6,088
of 99,702 outputs
Outputs of similar age from Lancet Oncology
#5
of 32 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 99,702 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.